Comparing Two Types of Drug-Eluting Stents
Author Information
Author(s): Jeon Ho Sung, Youn Young Jin, Lee Jung‐Hee, Park Young Jun, Son Jung‐Woo, Lee Jun‐Won, Ahn Min‐Soo, Ahn Sung Gyun, Kim Jang‐Young, Yoo Byung‐Su, Yoon Junghan
Primary Institution: Yonsei University Wonju College of Medicine
Hypothesis
This study aimed to compare the safety and efficacy of the Genoss and Orsiro ultrathin drug-eluting stents in real-world practice.
Conclusion
Both the Orsiro and Genoss stents showed comparable safety and efficacy during a 2-year follow-up period.
Supporting Evidence
- Both stents showed similar rates of device-oriented composite outcomes.
- The median follow-up period was 730 days.
- Patient demographics were well matched after propensity score matching.
- Clinical outcomes did not significantly differ between the two groups.
- Low event rates may be due to the exclusion of procedure-related myocardial infarctions.
- Use of potent antiplatelet therapy was common among patients.
- Radial access was predominantly used in the procedures.
- Future studies are needed to validate these findings.
Takeaway
Doctors tested two types of heart stents to see which one works better, and they found that both are pretty much the same.
Methodology
The study used a single-center prospective registry and included 483 patients treated with each stent after propensity score matching.
Potential Biases
Higher use of FFR and IVUS guidance in the Orsiro group may reflect operator preference.
Limitations
Potential selection bias remains despite propensity score matching, and the overall event rates were relatively low.
Participant Demographics
Mean age was 66.7 years, with 71.1% male, and 57.4% had hypertension.
Statistical Information
P-Value
0.847
Confidence Interval
0.49–2.09
Statistical Significance
p=0.847
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website